Curcumin-loaded magnetic nanoparticles for breast cancer therapeutics and imaging applications
Authors Yallapu M, Othman S, Curtis E, Bauer N, Chauhan, Kumar, Jaggi, Chauhan S
Received 17 December 2011
Accepted for publication 30 January 2012
Published 17 April 2012 Volume 2012:7 Pages 1761—1779
Review by Single anonymous peer review
Peer reviewer comments 4
Murali M Yallapu1, Shadi F Othman2, Evan T Curtis2, Nichole A Bauer1, Neeraj Chauhan1,3, Deepak Kumar4,5, Meena Jaggi1,3,6, Subhash C Chauhan1,3,6
1Cancer Biology Research Center, Sanford Research/University of South Dakota, Sioux Falls, SD, 2Department of Biological Systems Engineering, University of Nebraska–Lincoln, Lincoln, NE, 3Basic Biomedical Science Division, Sanford School of Medicine, University of South Dakota, Sioux Falls, SD, 4Cancer Research Laboratory, Department of Biology, University of the District of Columbia, 5Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, 6Department of Obstetrics/Gynecology, Sanford School of Medicine, University of South Dakota, Sioux Falls, SD, USA
Background: The next generation magnetic nanoparticles (MNPs) with theranostic applications have attracted significant attention and will greatly improve nanomedicine in cancer therapeutics. Such novel MNP formulations must have ultra-low particle size, high inherent magnetic properties, effective imaging, drug targeting, and drug delivery properties. To achieve these characteristic properties, a curcumin-loaded MNP (MNP-CUR) formulation was developed.
Methods: MNPs were prepared by chemical precipitation method and loaded with curcumin (CUR) using diffusion method. The physicochemical properties of MNP-CUR were characterized using dynamic light scattering, transmission electron microscopy, and spectroscopy. The internalization of MNP-CUR was achieved after 6 hours incubation with MDA-MB-231 breast cancer cells. The anticancer potential was evaluated by a tetrazolium-based dye and colony formation assays. Further, to prove MNP-CUR results in superior therapeutic effects over CUR, the mitochondrial membrane potential integrity and reactive oxygen species generation were determined. Magnetic resonance imaging capability and magnetic targeting property were also evaluated.
Results: MNP-CUR exhibited individual particle grain size of ~9 nm and hydrodynamic average aggregative particle size of ~123 nm. Internalized MNP-CUR showed a preferential uptake in MDA-MB-231 cells in a concentration-dependent manner and demonstrated accumulation throughout the cell, which indicates that particles are not attached on the cell surface but internalized through endocytosis. MNP-CUR displayed strong anticancer properties compared to free CUR. MNP-CUR also amplified loss of potential integrity and generation of reactive oxygen species upon treatment compared to free CUR. Furthermore, MNP-CUR exhibited superior magnetic resonance imaging characteristics and significantly increased the targeting capability of CUR.
Conclusion: MNP-CUR exhibits potent anticancer activity along with imaging and magnetic targeting capabilities. This approach can be extended to preclinical and clinical use and may have importance in cancer treatment and cancer imaging in the future. Further, if these nanoparticles can functionalize with antibody/ligands, they will serve as novel platforms for multiple biomedical applications.
Keywords: magnetic nanoparticles, drug delivery systems, magnetic resonance imaging, nanomedicine, cancer therapeutics, biomedical applications
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]